Cellerys AG announces start of immune tolerance trial RED4MS trial in multiple sclerosis!

We are pleased to announce that we are now screening the first patients for inclusion in our RED4MS phase IB/IIA clinical study. This important trial will be conducted in 4 countries across Europe and aims to demonstrate the power of immune tolerizing approaches for patients with multiple sclerosis.

Study Details | Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis | ClinicalTrials.gov